Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Morschhauser

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2007
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaF Morschhauser, J F Seymour, H C Kluin-Nelemans, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 1, 2013
Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern eraA M Evens, S Choquet, A R Kroll-Desrosiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2023
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trialA S Cottereau, L Rebaud, J Trotman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2012
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)N Ketterer, B Coiffier, C Thieblemont, et al.
Blood|July 14, 2017
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 studyR-O Casasnovas, L Ysebaert, C Thieblemont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphomaM Dreyling, F Morschhauser, K Bouabdallah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2019
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†H Ghesquieres, M Chevrier, M Laadhari, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 5, 2015
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trialR U Trappe, S Choquet, D Dierickx, et al.
Hematological Oncology|October 1, 2024
Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA studyC Bommier, M Donzel, C Rossi, et al.
Leukemia|February 25, 2015
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypesM Pfeifer, B Zheng, T Erdmann, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2007
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaF Morschhauser, J F Seymour, H C Kluin-Nelemans, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 1, 2013
Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern eraA M Evens, S Choquet, A R Kroll-Desrosiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2023
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trialA S Cottereau, L Rebaud, J Trotman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2012
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B)N Ketterer, B Coiffier, C Thieblemont, et al.
Blood|July 14, 2017
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 studyR-O Casasnovas, L Ysebaert, C Thieblemont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphomaM Dreyling, F Morschhauser, K Bouabdallah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2019
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†H Ghesquieres, M Chevrier, M Laadhari, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 5, 2015
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trialR U Trappe, S Choquet, D Dierickx, et al.
Hematological Oncology|October 1, 2024
Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA studyC Bommier, M Donzel, C Rossi, et al.
Leukemia|February 25, 2015
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypesM Pfeifer, B Zheng, T Erdmann, et al.
Pageof 5